Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception
about
Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activitiesNonsteroidal androgen receptor ligands: versatile syntheses and biological data.Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.Hormonal approaches to male contraception.Male contraception.Deciphering the selective androgen receptor modulators paradigm.Noncanonical mechanisms to regulate nuclear receptor signaling.Recent advances in the development of selective androgen receptor modulators.Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral TissuesUpdate on male hormonal contraception: is the vasectomy in jeopardy?Improving selective androgen receptor modulator discovery and preclinical evaluation.Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls.Testosterone represses ubiquitin ligases atrogin-1 and Murf-1 expression in an androgen-sensitive rat skeletal muscle in vivo.Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation.Recent discoveries and developments of androgen receptor based therapy for prostate cancer
P2860
Q24633969-0968CEC2-0DF2-48B8-A87D-C37D7CC86F04Q30829176-1BCACDCD-F3F5-4F4A-8F3B-E02CDE2C58E9Q34035236-08C65162-25FA-4826-8C36-81FAF8540EAFQ34135231-A4FFFB95-EA92-4E42-8616-D813D59B51AFQ34316731-71C1F9F5-E0A3-4788-A0EB-DE4D19DF06D4Q34317005-9E44CC76-BCDB-4B3F-9F76-EF0195E2EE10Q34338685-77AE1D63-2002-4A95-95DD-783E37BF07A9Q34985529-CC5BC507-6274-41C6-A193-A3017EB769C5Q36331791-CBCB7177-F220-4822-A2DA-E8CB1F820BE2Q37718605-FEAD9E81-30C7-4D45-8CE1-749D1227096DQ38088367-47F3D883-DE4A-4B1B-8416-D5490D8C856DQ39734819-88E8AA97-5C82-4271-A0EA-FC2A124F4745Q43238366-68774877-3556-486B-A0AB-3A52DDEF54EDQ47786450-27A3ED09-1448-4AE9-BEFA-C0B3A5D5F26EQ56621622-9C07023C-304B-46DD-A7FF-27CE29C49B6E
P2860
Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Preclinical characterization o ...... or hormonal male contraception
@ast
Preclinical characterization o ...... or hormonal male contraception
@en
Preclinical characterization o ...... or hormonal male contraception
@nl
type
label
Preclinical characterization o ...... or hormonal male contraception
@ast
Preclinical characterization o ...... or hormonal male contraception
@en
Preclinical characterization o ...... or hormonal male contraception
@nl
prefLabel
Preclinical characterization o ...... or hormonal male contraception
@ast
Preclinical characterization o ...... or hormonal male contraception
@en
Preclinical characterization o ...... or hormonal male contraception
@nl
P2093
P2860
P356
P1433
P1476
Preclinical characterization o ...... or hormonal male contraception
@en
P2093
Amanda Jones
Dong Jin Hwang
Duane D Miller
Jiyun Chen
P2860
P304
P356
10.1210/EN.2008-0674
P407
P577
2008-09-04T00:00:00Z